In terms of mechanism, IGFBP2/ITGA5 enhances the expression of CXCL1 by activating STAT3, thereby promoting gefitinib resistance in non-small cell lung cancer (Fig. 11). Here, CXCL1 is linked to non-small cell lung carcinoma.